BACKGROUND: After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance. METHODS: In a large multicountry cohort of patients starting standard first-line ART in six African countries, pol genotyping was retrospectively performed if viral load (VL) ≥1000 cps/mL. Pretreatment drug resistance was defined as a decreased susceptibility to ≥1 prescribed drug. We assessed the effect of pretreatment drug resistance on all-cause mortality, new AIDS events and switch to second-line ART due to presumed treatment failure, using Cox models. RESULTS: Among 2579 participants for whom a pretreatment genotype was available, 5.5% had pretreatment drug resistance. Pretreatment drug resistance was associated with an increased risk of regimen switch (adjusted hazard ratio [aHR] 3.80; 95% confidence interval [CI], 1.49-9.68; P = .005) but was not associated with mortality (aHR 0.75, 95% CI, .24-2.35; P = .617) or new AIDS events (aHR 1.06, 95% CI, .68-1.64; P = .807). During three years of follow up, 106 (4.1%) participants switched to second-line, of whom 18 (17.0%) switched with VL < 1000 cps/mL, 7 (6.6%) with VL ≥ 1000 cps/mL and no drug resistance mutations (DRMs), 46 (43.4%) with VL ≥ 1000 cps/mL and ≥1 DRMs; no HIV RNA data was available for 32 (30.2%) participants. CONCLUSIONS: Given rising pretreatment HIV drug resistance levels in sub-Saharan Africa, these findings underscore the need for expanded access to second-line ART. VL monitoring can improve the accuracy of failure detection and efficiency of switching practices.
BACKGROUND: After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance. METHODS: In a large multicountry cohort of patients starting standard first-line ART in six African countries, pol genotyping was retrospectively performed if viral load (VL) ≥1000 cps/mL. Pretreatment drug resistance was defined as a decreased susceptibility to ≥1 prescribed drug. We assessed the effect of pretreatment drug resistance on all-cause mortality, new AIDS events and switch to second-line ART due to presumed treatment failure, using Cox models. RESULTS: Among 2579 participants for whom a pretreatment genotype was available, 5.5% had pretreatment drug resistance. Pretreatment drug resistance was associated with an increased risk of regimen switch (adjusted hazard ratio [aHR] 3.80; 95% confidence interval [CI], 1.49-9.68; P = .005) but was not associated with mortality (aHR 0.75, 95% CI, .24-2.35; P = .617) or new AIDS events (aHR 1.06, 95% CI, .68-1.64; P = .807). During three years of follow up, 106 (4.1%) participants switched to second-line, of whom 18 (17.0%) switched with VL < 1000 cps/mL, 7 (6.6%) with VL ≥ 1000 cps/mL and no drug resistance mutations (DRMs), 46 (43.4%) with VL ≥ 1000 cps/mL and ≥1 DRMs; no HIV RNA data was available for 32 (30.2%) participants. CONCLUSIONS: Given rising pretreatment HIV drug resistance levels in sub-Saharan Africa, these findings underscore the need for expanded access to second-line ART. VL monitoring can improve the accuracy of failure detection and efficiency of switching practices.
Authors: Mark W Tenforde; Margaret Mokomane; Tshepo Leeme; Raju K K Patel; Nametso Lekwape; Chandapiwa Ramodimoosi; Bonno Dube; Elizabeth A Williams; Kelebeletse O Mokobela; Ephraim Tawanana; Tlhagiso Pilatwe; William J Hurt; Hannah Mitchell; Doreen L Banda; Hunter Stone; Mooketsi Molefi; Kabelo Mokgacha; Heston Phillips; Paul C Mullan; Andrew P Steenhoff; Yohana Mashalla; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Pascale Ondoa; Andrea A Kim; T Sonia Boender; Guoqing Zhang; Stefanie Kroeze; Jeffrey Wiener; Tobias Rinke de Wit; John Nkengasong Journal: AIDS Res Hum Retroviruses Date: 2020-08-27 Impact factor: 2.205
Authors: Suzanne M McCluskey; Guinevere Q Lee; Kimia Kamelian; Annet Kembabazi; Nicholas Musinguzi; Mwebesa B Bwana; Conrad Muzoora; Jessica E Haberer; Peter W Hunt; Jeffrey N Martin; Yap Boum; David R Bangsberg; P Richard Harrigan; Mark J Siedner Journal: AIDS Patient Care STDS Date: 2018-07 Impact factor: 5.078
Authors: Landon Myer; Andrew D Redd; Elton Mukonda; Briana A Lynch; Tamsin K Phillips; Anna Eisenberg; Nei-Yuan Hsiao; Adam Capoferri; Alison Zerbe; William Clarke; Maia Lesosky; Autumn Breaud; James McIntyre; Daniel Bruno; Craig Martens; Elaine J Abrams; Steven J Reynolds Journal: Clin Infect Dis Date: 2020-01-16 Impact factor: 9.079
Authors: Fred Kyeyune; Richard M Gibson; Immaculate Nankya; Colin Venner; Samar Metha; Juliet Akao; Emmanuel Ndashimye; Cissy M Kityo; Robert A Salata; Peter Mugyenyi; Eric J Arts; Miguel E Quiñones-Mateu Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191
Authors: Silvia Bertagnolio; Rachel L Beanland; Michael R Jordan; Meg Doherty; Gottfried Hirnschall Journal: J Infect Dis Date: 2017-12-01 Impact factor: 5.226
Authors: Babafemi O Taiwo; Kehinde M Kuti; Lisa M Kuhns; Olayinka Omigbodun; Olutosin Awolude; Adedotun Adetunji; Baiba Berzins; Patrick Janulis; Amy K Johnson; Ogochukwu Okonkwor; Bibilola D Oladeji; Abigail Muldoon; Olubusuyi M Adewumi; Paul Amoo; Hannah Atunde; Bill Kapogiannis; Robert Garofalo Journal: J Acquir Immune Defic Syndr Date: 2021-08-01 Impact factor: 3.771
Authors: Anton Reepalu; Taye Tolera Balcha; Erik Sturegård; Patrik Medstrand; Per Björkman Journal: Open Forum Infect Dis Date: 2017-10-08 Impact factor: 3.835